Focus: Bracco is a specialized imaging pharmaceutical company headquartered in Milan, Italy, with 1,001-5,000 employees focused on contrast agents and diagnostic imaging solutions across cardiovascular, gastroenterology, and hematology.
Profile data last refreshed 10h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Bracco to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Bracco
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Bracco's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Primary growth driver with exclusive patent protection through 2029; used for cerebral vascular imaging in stroke and tumor evaluation.
Mature oral contrast media at peak market penetration; generates steady cash flow in routine GI imaging.
Legacy contrast agent; patent expiration imminent, facing generic competition.
Aging renal contrast product with approaching loss of exclusivity; declining market share.
Aging ionic contrast formulation; significant patent erosion risk.
Non-ionic iodinated contrast medium; patent cliff in October 2028 will trigger generic competition and revenue decline.
41 discontinued, 23 duplicate formulations not shown
Bracco and ACIST Medical Systems Announce U.S. FDA Clearance of ACIST Pro™ Diagnostic System - BioSpace
Bracco and ACIST Medical Systems Announce U.S. FDA Clearance of ACIST Pro™ Diagnostic System BioSpace
Bracco and ACIST Medical Systems Announce U.S. FDA Clearance of ACIST Pro™ Diagnostic System - PR Newswire
Bracco and ACIST Medical Systems Announce U.S. FDA Clearance of ACIST Pro™ Diagnostic System PR Newswire
Bracco Launches BubbleGen™ Early Access Program for Microbubble-Based Cell Selection and Activation at ISCT - STT Info
Bracco Launches BubbleGen™ Early Access Program for Microbubble-Based Cell Selection and Activation at ISCT STT Info
Bracco Imaging and NYU Langone Health Announce Strategic Alliance Agreement to Advance Medical Imaging Innovation - PA Media
Bracco Imaging and NYU Langone Health Announce Strategic Alliance Agreement to Advance Medical Imaging Innovation PA Media
Bracco Imaging and NYU Langone Health Announce Strategic Alliance Agreement to Advance Medical Imaging Innovation - PR Newswire
Bracco Imaging and NYU Langone Health Announce Strategic Alliance Agreement to Advance Medical Imaging Innovation PR Newswire
8-K Filing: Ionetix Corp / DE / (CIK 0002108121) — CURRENT REPORT
CURRENT REPORT
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo